Loading…

2021 Update on the Clinical Management and Diagnosis of Kawasaki Disease

Purpose of Review Provide an updated review of the clinical management and diagnosis of Kawasaki disease with inclusion of potential diagnostic difficulties with multisystem inflammatory syndrome in children (MIS-C) given the ongoing COVID-19 pandemic. Recent Findings Adjunctive corticosteroid thera...

Full description

Saved in:
Bibliographic Details
Published in:Current infectious disease reports 2021-03, Vol.23 (3), p.3-3, Article 3
Main Authors: Zhu, Frank, Ang, Jocelyn Y.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c485t-537ee7a5da39700b5eb439e40339c456327dca04352b16347d6fce77c71350dd3
cites cdi_FETCH-LOGICAL-c485t-537ee7a5da39700b5eb439e40339c456327dca04352b16347d6fce77c71350dd3
container_end_page 3
container_issue 3
container_start_page 3
container_title Current infectious disease reports
container_volume 23
creator Zhu, Frank
Ang, Jocelyn Y.
description Purpose of Review Provide an updated review of the clinical management and diagnosis of Kawasaki disease with inclusion of potential diagnostic difficulties with multisystem inflammatory syndrome in children (MIS-C) given the ongoing COVID-19 pandemic. Recent Findings Adjunctive corticosteroid therapy has been shown to reduce the rate of coronary artery dilation in children at high risk for IVIG resistance in multiple Japanese clinical studies (most notably RAISE study group). Additional adjunctive therapies (etanercept, infliximab, cyclosporin) may also provide limited benefit, but data is limited to single studies and subgroups of patients with cardiac abnormalities. The efficacy of other agents (atorvastatin, doxycycline) is currently being investigated. MIS-C is a clinically distinct entity from KD with broad clinical manifestations and multiorgan involvement (cardiac, GI, hematologic, dermatologic, respiratory, renal). MIS-C with Kawasaki manifestations is more commonly seen in children < 5 years of age. Summary The 2017 American Heart Association (AHA) treatment guidelines have included changes in aspirin dosing (including both 80–100 mg/kg/day and 30–50 mg/kg/day treatment options), consideration of the use of adjuvant corticosteroid therapy in patients at high risk of IVIG resistance, and the change in steroid regimen for refractory KD to include both pulse-dose IVMP and longer course of prednisolone with an oral taper. A significant proportion of children diagnosed with MIS-C, a post-infectious syndrome of SARS-CoV-2 infection, meet criteria for Kawasaki disease. Further investigation is warranted to further delineate these conditions and optimize treatment of these conditions given the ongoing COVID-19 pandemic.
doi_str_mv 10.1007/s11908-021-00746-1
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2632146734</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2486884650</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-537ee7a5da39700b5eb439e40339c456327dca04352b16347d6fce77c71350dd3</originalsourceid><addsrcrecordid>eNp9kDtPwzAYRS0EoqXwBxiQJRaWgO3Pjt0RlUcRRSx0tpzka0lJnRInQvx7XMJDYmDy69xr-xByzNk5Z0xfBM7HzCRM8CQuZZrwHTLkCmQCXKa727mABIzUA3IQwooxETmzTwYAykguzZBMRYzT-aZwLdLa0_YZ6aQqfZm7ij4475a4Rt9S5wt6Vbqlr0MZaL2g9-7NBfdSxt2ALuAh2Vu4KuDR1zgi85vrp8k0mT3e3k0uZ0kujWoTBRpRO1U4GGvGMoWZhDFKBjDOpUpB6CJ3TIISGU9B6iJd5Kh1rjkoVhQwImd976apXzsMrV2XIceqch7rLlgRK-LvNciInv5BV3XX-Pg6K6RJjZGpYpESPZU3dQgNLuymKdeuebec2a1n23u2UZT99Gx5DJ18VXfZGoufyLfYCEAPhHjkl9j83v1P7QePcITB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2486884650</pqid></control><display><type>article</type><title>2021 Update on the Clinical Management and Diagnosis of Kawasaki Disease</title><source>Springer Nature</source><creator>Zhu, Frank ; Ang, Jocelyn Y.</creator><creatorcontrib>Zhu, Frank ; Ang, Jocelyn Y.</creatorcontrib><description>Purpose of Review Provide an updated review of the clinical management and diagnosis of Kawasaki disease with inclusion of potential diagnostic difficulties with multisystem inflammatory syndrome in children (MIS-C) given the ongoing COVID-19 pandemic. Recent Findings Adjunctive corticosteroid therapy has been shown to reduce the rate of coronary artery dilation in children at high risk for IVIG resistance in multiple Japanese clinical studies (most notably RAISE study group). Additional adjunctive therapies (etanercept, infliximab, cyclosporin) may also provide limited benefit, but data is limited to single studies and subgroups of patients with cardiac abnormalities. The efficacy of other agents (atorvastatin, doxycycline) is currently being investigated. MIS-C is a clinically distinct entity from KD with broad clinical manifestations and multiorgan involvement (cardiac, GI, hematologic, dermatologic, respiratory, renal). MIS-C with Kawasaki manifestations is more commonly seen in children &lt; 5 years of age. Summary The 2017 American Heart Association (AHA) treatment guidelines have included changes in aspirin dosing (including both 80–100 mg/kg/day and 30–50 mg/kg/day treatment options), consideration of the use of adjuvant corticosteroid therapy in patients at high risk of IVIG resistance, and the change in steroid regimen for refractory KD to include both pulse-dose IVMP and longer course of prednisolone with an oral taper. A significant proportion of children diagnosed with MIS-C, a post-infectious syndrome of SARS-CoV-2 infection, meet criteria for Kawasaki disease. Further investigation is warranted to further delineate these conditions and optimize treatment of these conditions given the ongoing COVID-19 pandemic.</description><identifier>ISSN: 1523-3847</identifier><identifier>EISSN: 1534-3146</identifier><identifier>DOI: 10.1007/s11908-021-00746-1</identifier><identifier>PMID: 33584148</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Coronaviruses ; COVID-19 ; Infectious Diseases ; Kawasaki disease ; Medicine ; Medicine &amp; Public Health ; Monoclonal antibodies ; Multisystem inflammatory syndrome in children ; Pandemics ; Pediatric Infectious Diseases (I Brook ; Section Editor ; Severe acute respiratory syndrome coronavirus 2 ; Topical Collection on Pediatric Infectious Diseases</subject><ispartof>Current infectious disease reports, 2021-03, Vol.23 (3), p.3-3, Article 3</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021. corrected publication 2021</rights><rights>The Author(s) 2021.</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021. corrected publication 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-537ee7a5da39700b5eb439e40339c456327dca04352b16347d6fce77c71350dd3</citedby><cites>FETCH-LOGICAL-c485t-537ee7a5da39700b5eb439e40339c456327dca04352b16347d6fce77c71350dd3</cites><orcidid>0000-0003-0644-3876</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33584148$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhu, Frank</creatorcontrib><creatorcontrib>Ang, Jocelyn Y.</creatorcontrib><title>2021 Update on the Clinical Management and Diagnosis of Kawasaki Disease</title><title>Current infectious disease reports</title><addtitle>Curr Infect Dis Rep</addtitle><addtitle>Curr Infect Dis Rep</addtitle><description>Purpose of Review Provide an updated review of the clinical management and diagnosis of Kawasaki disease with inclusion of potential diagnostic difficulties with multisystem inflammatory syndrome in children (MIS-C) given the ongoing COVID-19 pandemic. Recent Findings Adjunctive corticosteroid therapy has been shown to reduce the rate of coronary artery dilation in children at high risk for IVIG resistance in multiple Japanese clinical studies (most notably RAISE study group). Additional adjunctive therapies (etanercept, infliximab, cyclosporin) may also provide limited benefit, but data is limited to single studies and subgroups of patients with cardiac abnormalities. The efficacy of other agents (atorvastatin, doxycycline) is currently being investigated. MIS-C is a clinically distinct entity from KD with broad clinical manifestations and multiorgan involvement (cardiac, GI, hematologic, dermatologic, respiratory, renal). MIS-C with Kawasaki manifestations is more commonly seen in children &lt; 5 years of age. Summary The 2017 American Heart Association (AHA) treatment guidelines have included changes in aspirin dosing (including both 80–100 mg/kg/day and 30–50 mg/kg/day treatment options), consideration of the use of adjuvant corticosteroid therapy in patients at high risk of IVIG resistance, and the change in steroid regimen for refractory KD to include both pulse-dose IVMP and longer course of prednisolone with an oral taper. A significant proportion of children diagnosed with MIS-C, a post-infectious syndrome of SARS-CoV-2 infection, meet criteria for Kawasaki disease. Further investigation is warranted to further delineate these conditions and optimize treatment of these conditions given the ongoing COVID-19 pandemic.</description><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Infectious Diseases</subject><subject>Kawasaki disease</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Monoclonal antibodies</subject><subject>Multisystem inflammatory syndrome in children</subject><subject>Pandemics</subject><subject>Pediatric Infectious Diseases (I Brook</subject><subject>Section Editor</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Topical Collection on Pediatric Infectious Diseases</subject><issn>1523-3847</issn><issn>1534-3146</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kDtPwzAYRS0EoqXwBxiQJRaWgO3Pjt0RlUcRRSx0tpzka0lJnRInQvx7XMJDYmDy69xr-xByzNk5Z0xfBM7HzCRM8CQuZZrwHTLkCmQCXKa727mABIzUA3IQwooxETmzTwYAykguzZBMRYzT-aZwLdLa0_YZ6aQqfZm7ij4475a4Rt9S5wt6Vbqlr0MZaL2g9-7NBfdSxt2ALuAh2Vu4KuDR1zgi85vrp8k0mT3e3k0uZ0kujWoTBRpRO1U4GGvGMoWZhDFKBjDOpUpB6CJ3TIISGU9B6iJd5Kh1rjkoVhQwImd976apXzsMrV2XIceqch7rLlgRK-LvNciInv5BV3XX-Pg6K6RJjZGpYpESPZU3dQgNLuymKdeuebec2a1n23u2UZT99Gx5DJ18VXfZGoufyLfYCEAPhHjkl9j83v1P7QePcITB</recordid><startdate>20210301</startdate><enddate>20210301</enddate><creator>Zhu, Frank</creator><creator>Ang, Jocelyn Y.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0644-3876</orcidid></search><sort><creationdate>20210301</creationdate><title>2021 Update on the Clinical Management and Diagnosis of Kawasaki Disease</title><author>Zhu, Frank ; Ang, Jocelyn Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-537ee7a5da39700b5eb439e40339c456327dca04352b16347d6fce77c71350dd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Infectious Diseases</topic><topic>Kawasaki disease</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Monoclonal antibodies</topic><topic>Multisystem inflammatory syndrome in children</topic><topic>Pandemics</topic><topic>Pediatric Infectious Diseases (I Brook</topic><topic>Section Editor</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Topical Collection on Pediatric Infectious Diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhu, Frank</creatorcontrib><creatorcontrib>Ang, Jocelyn Y.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Current infectious disease reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhu, Frank</au><au>Ang, Jocelyn Y.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>2021 Update on the Clinical Management and Diagnosis of Kawasaki Disease</atitle><jtitle>Current infectious disease reports</jtitle><stitle>Curr Infect Dis Rep</stitle><addtitle>Curr Infect Dis Rep</addtitle><date>2021-03-01</date><risdate>2021</risdate><volume>23</volume><issue>3</issue><spage>3</spage><epage>3</epage><pages>3-3</pages><artnum>3</artnum><issn>1523-3847</issn><eissn>1534-3146</eissn><abstract>Purpose of Review Provide an updated review of the clinical management and diagnosis of Kawasaki disease with inclusion of potential diagnostic difficulties with multisystem inflammatory syndrome in children (MIS-C) given the ongoing COVID-19 pandemic. Recent Findings Adjunctive corticosteroid therapy has been shown to reduce the rate of coronary artery dilation in children at high risk for IVIG resistance in multiple Japanese clinical studies (most notably RAISE study group). Additional adjunctive therapies (etanercept, infliximab, cyclosporin) may also provide limited benefit, but data is limited to single studies and subgroups of patients with cardiac abnormalities. The efficacy of other agents (atorvastatin, doxycycline) is currently being investigated. MIS-C is a clinically distinct entity from KD with broad clinical manifestations and multiorgan involvement (cardiac, GI, hematologic, dermatologic, respiratory, renal). MIS-C with Kawasaki manifestations is more commonly seen in children &lt; 5 years of age. Summary The 2017 American Heart Association (AHA) treatment guidelines have included changes in aspirin dosing (including both 80–100 mg/kg/day and 30–50 mg/kg/day treatment options), consideration of the use of adjuvant corticosteroid therapy in patients at high risk of IVIG resistance, and the change in steroid regimen for refractory KD to include both pulse-dose IVMP and longer course of prednisolone with an oral taper. A significant proportion of children diagnosed with MIS-C, a post-infectious syndrome of SARS-CoV-2 infection, meet criteria for Kawasaki disease. Further investigation is warranted to further delineate these conditions and optimize treatment of these conditions given the ongoing COVID-19 pandemic.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>33584148</pmid><doi>10.1007/s11908-021-00746-1</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-0644-3876</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1523-3847
ispartof Current infectious disease reports, 2021-03, Vol.23 (3), p.3-3, Article 3
issn 1523-3847
1534-3146
language eng
recordid cdi_proquest_miscellaneous_2632146734
source Springer Nature
subjects Coronaviruses
COVID-19
Infectious Diseases
Kawasaki disease
Medicine
Medicine & Public Health
Monoclonal antibodies
Multisystem inflammatory syndrome in children
Pandemics
Pediatric Infectious Diseases (I Brook
Section Editor
Severe acute respiratory syndrome coronavirus 2
Topical Collection on Pediatric Infectious Diseases
title 2021 Update on the Clinical Management and Diagnosis of Kawasaki Disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T17%3A07%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=2021%20Update%20on%20the%20Clinical%20Management%20and%20Diagnosis%20of%20Kawasaki%20Disease&rft.jtitle=Current%20infectious%20disease%20reports&rft.au=Zhu,%20Frank&rft.date=2021-03-01&rft.volume=23&rft.issue=3&rft.spage=3&rft.epage=3&rft.pages=3-3&rft.artnum=3&rft.issn=1523-3847&rft.eissn=1534-3146&rft_id=info:doi/10.1007/s11908-021-00746-1&rft_dat=%3Cproquest_cross%3E2486884650%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c485t-537ee7a5da39700b5eb439e40339c456327dca04352b16347d6fce77c71350dd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2486884650&rft_id=info:pmid/33584148&rfr_iscdi=true